Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2

At a glance

Company: Quantum BioPharma Ltd.
Ticker: NASDAQ: QNTM, CSE: QNTM
Announcement: Earnings

Key figures

Year-over-year operating expense reduction: 53%
Operating expenses: $2.29 million
Year-over-year general and administrative expense reduction: 47%
General and administrative expenses: $1.76 million
Cash, cash equivalents and digital assets at June 30: approximately $9.5 million
Cash, cash equivalents and digital assets at Dec. 31, 2025: $4.1 million

Products and programs

Lucid-MS

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) reported second-quarter 2026 financial and operational results, including a 53% year-over-year reduction in operating expenses to $2.29 million and a 47% decrease in general and administrative expenses to $1.76 million. Combined cash, cash equivalents and digital […]

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.

reported second-quarter 2026 financial and operational results, including a 53% year-over-year reduction in operating expenses to $2.29 million and a 47% decrease in general and administrative expenses to $1.76 million. Combined cash, cash equivalents and digital assets totaled approximately $9.5 million as of June 30, up from $4.1 million at Dec. 31, 2025, with management stating that current liquidity is sufficient to fund planned operations to at least October 2027 assuming the first-half 2026 cash burn rate. Subsequent to quarter-end, the FDA approved Quantum’s Investigational New Drug (“IND”) application for Lucid-MS, clearing the company to proceed with a randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with progressive multiple sclerosis.

To view the full press release, visit https://nnw.fm/dlAAe

About Quantum BioPharma Ltd.

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD(TM) and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

In brief

Quantum BioPharma reported second-quarter 2026 results, saying operating expenses fell 53% year over year to $2.29 million and general and administrative expenses declined 47% to $1.76 million. The company reported approximately $9.5 million in combined cash, cash equivalents and digital assets at June 30, compared with $4.1 million at Dec. 31, 2025. Management said this liquidity can support planned operations through at least October 2027 if the first-half 2026 cash burn rate continues. After the quarter ended, the FDA approved the company’s Investigational New Drug application for Lucid-MS. Quantum says the approval allows it to proceed with a randomized, double-blind, placebo-controlled Phase 2 trial in patients with progressive multiple sclerosis.

Key takeaways

Operating expenses decreased 53% year over year to $2.29 million, the company reported.
Combined cash, cash equivalents and digital assets were approximately $9.5 million at June 30.
The FDA approved the IND application for Lucid-MS after quarter-end.
Quantum can proceed with a Phase 2 Lucid-MS trial in progressive multiple sclerosis patients.

SEC filings

Earlier from Quantum BioPharma Ltd.

Back to News Center